PolyPid (PYPD) deputy CEO discloses extensive employee stock options

Rhea-AI Filing Summary

PolyPid Ltd. deputy CEO and EVP R&D Hazan Dalit Fellous has filed an initial Form 3 reporting holdings of employee stock options over the company’s ordinary shares. The filing lists multiple option grants with exercise prices ranging from 2.6700 to 92.8900 per share and expirations between 2026 and 2035.

Several grants are disclosed as fully vested based on earlier grant dates, while others vest on a quarterly schedule through dates such as May 9, 2026, August 7, 2027, May 6, 2028, and May 12, 2029. This Form 3 records existing derivative holdings and does not show any new purchases or sales.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Hazan Dalit Fellous

(Last) (First) (Middle)

C/O POLYPID LTD.

18 HASIVIM STREET

(Street)

PETACH TIKVA 495376

(City) (State) (Zip)

ISRAEL

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
PolyPid Ltd. [ PYPD ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Deputy CEO, EVP, RD, CRA

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock option (right to buy)	04/04/2017	04/05/2026	Ordinary Shares	73(1)	$92.89	D
Employee Stock option (right to buy)	08/25/2017	08/24/2026	Ordinary Shares	47(2)	$92.89	D
Employee Stock option (right to buy)	02/02/2018	11/02/2027	Ordinary Shares	199(3)	$23.07	D
Employee Stock option (right to buy)	05/06/2020	02/06/2030	Ordinary Shares	80(4)	$23.07	D
Employee Stock option (right to buy)	06/11/2021	06/11/2030	Ordinary Shares	1,832(5)	$23.07	D
Employee Stock option (right to buy)	05/09/2023	05/09/2032	Ordinary Shares	2,000(6)	$23.07	D
Employee Stock option (right to buy)	08/09/2022	08/09/2031	Ordinary Shares	1,165(7)	$23.07	D
Employee Stock option (right to buy)	08/07/2024	08/07/2033	Ordinary Shares	14,667(8)	$11.01	D
Employee Stock option (right to buy)	08/06/2024	05/06/2034	Ordinary Shares	90,000(9)	$4.64	D
Employee Stock option (right to buy)	06/09/2025	05/06/2034	Ordinary Shares	60,000(10)	$4.64	D
Employee Stock option (right to buy)	08/12/2025	05/12/2035	Ordinary Shares	66,000(11)	$2.67	D
Employee Stock option (right to buy)	06/09/2025	05/12/2035	Ordinary Shares	44,000(12)	$2.67	D

Explanation of Responses:

1. The options were granted on April 5, 2016 and fully vested as of April 5, 2019.

2. The options were granted on August 24, 2016 and fully vested as of August 24, 2019.

3. The options were granted on November 2, 2017 and fully vested as of November 2, 2020.

4. The options were granted on February 6, 2020 and fully vested as of February 6, 2023.

5. The options were granted on June 11, 2020 and fully vested as of June 11, 2024.

6. The options were granted on May 9, 2022 and vest on a quarterly basis beginning May 9, 2023 until May 9, 2026.

7. The options were granted on August 9, 2021 and fully vested as of August 9, 2025.

8. The options were granted on August 7, 2023 and vest on a quarterly basis beginning August 7, 2024 until August 7, 2027.

9. The options were granted on May 6, 2024 and vest on a quarterly basis until May 6, 2028.

10. The options were granted on May 6, 2024 and vest on a quarterly basis until May 6, 2026.

11. The options were granted on May 12, 2025 and vest on a quarterly basis until May 12, 2029.

12. The options were granted on May 12, 2025 and vest on a quarterly basis until May 12, 2027.

	/s/ Dalit Fellous Hazan	03/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does PolyPid (PYPD) deputy CEO report in this Form 3?

The deputy CEO reports existing employee stock options over PolyPid ordinary shares. These options have various exercise prices, expiration dates, and vesting schedules, documenting her current derivative holdings rather than new market transactions.

Are there any share purchases or sales in PolyPid (PYPD) deputy CEO’s Form 3?

No, the Form 3 for PolyPid’s deputy CEO shows no reported purchases or sales. It only lists option positions as of the reporting date, with transaction codes and summaries indicating holdings rather than open-market trades or exercises.

What option exercise prices are disclosed for PolyPid (PYPD) deputy CEO?

The filing lists several exercise prices, including 92.8900, 23.0700, 11.0100, 4.6400, and 2.6700 per share. These apply to different option grants over PolyPid ordinary shares with distinct vesting and expiration dates.

When do the reported PolyPid (PYPD) options held by the deputy CEO expire?

The options expire on various dates from 2026 through 2035. Specific expirations include April 5, 2026, August 24, 2026, November 2, 2027, and later dates such as May 6, 2034 and May 12, 2035 for newer grants.

How do PolyPid (PYPD) deputy CEO’s options vest according to the Form 3 footnotes?

Footnotes show some grants are fully vested, tied to dates like April 5, 2019 and August 9, 2025. Others vest on a quarterly basis through schedules ending May 9, 2026, August 7, 2027, May 6, 2028, and May 12, 2029.

What types of securities are reported in the PolyPid (PYPD) Form 3 for the deputy CEO?

The Form 3 reports only employee stock options (rights to buy) as derivative securities. Each option grant is linked to a number of underlying PolyPid ordinary shares, with detailed exercise prices, vesting terms, and expiration dates.